BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15126327)

  • 1. Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells.
    Uno F; Sasaki J; Nishizaki M; Carboni G; Xu K; Atkinson EN; Kondo M; Minna JD; Roth JA; Ji L
    Cancer Res; 2004 May; 64(9):2969-76. PubMed ID: 15126327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
    Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
    Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
    Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
    Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo.
    Ji L; Nishizaki M; Gao B; Burbee D; Kondo M; Kamibayashi C; Xu K; Yen N; Atkinson EN; Fang B; Lerman MI; Roth JA; Minna JD
    Cancer Res; 2002 May; 62(9):2715-20. PubMed ID: 11980673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
    Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R
    Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer.
    Ren J; Yu C; Wu S; Peng F; Jiang Q; Zhang X; Zhong G; Shi H; Chen X; Su X; Luo X; Zhu W; Wei Y
    Curr Cancer Drug Targets; 2014; 14(2):167-80. PubMed ID: 24410728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo.
    Ito I; Ji L; Tanaka F; Saito Y; Gopalan B; Branch CD; Xu K; Atkinson EN; Bekele BN; Stephens LC; Minna JD; Roth JA; Ramesh R
    Cancer Gene Ther; 2004 Nov; 11(11):733-9. PubMed ID: 15486560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1.
    Ivanova AV; Ivanov SV; Pascal V; Lumsden JM; Ward JM; Morris N; Tessarolo L; Anderson SK; Lerman MI
    J Pathol; 2007 Apr; 211(5):591-601. PubMed ID: 17318811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of tumor suppressor gene FUS1 expression by the untranslated regions of mRNA in human lung cancer cells.
    Lin J; Xu K; Gitanjali J; Roth JA; Ji L
    Biochem Biophys Res Commun; 2011 Jul; 410(2):235-41. PubMed ID: 21645495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo.
    Li L; Yu C; Ren J; Ye S; Ou W; Wang Y; Yang W; Zhong G; Chen X; Shi H; Su X; Chen L; Zhu W
    J Cancer Res Clin Oncol; 2014 Jun; 140(6):895-907. PubMed ID: 24659339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor FUS1 signaling pathway.
    Ji L; Roth JA
    J Thorac Oncol; 2008 Apr; 3(4):327-30. PubMed ID: 18379348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells.
    Kondo M; Ji L; Kamibayashi C; Tomizawa Y; Randle D; Sekido Y; Yokota J; Kashuba V; Zabarovsky E; Kuzmin I; Lerman M; Roth J; Minna JD
    Oncogene; 2001 Sep; 20(43):6258-62. PubMed ID: 11593436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer.
    Mao X; Seidlitz E; Ghosh K; Murakami Y; Ghosh HP
    Cancer Res; 2003 Nov; 63(22):7979-85. PubMed ID: 14633730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
    Lerman MI; Minna JD
    Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem reporter assay for myristoylated proteins post-translationally (TRAMPP) identifies novel substrates for post-translational myristoylation: PKCĪµ, a case study.
    Martin DD; Ahpin CY; Heit RJ; Perinpanayagam MA; Yap MC; Veldhoen RA; Goping IS; Berthiaume LG
    FASEB J; 2012 Jan; 26(1):13-28. PubMed ID: 21965604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy.
    Ohtani S; Iwamaru A; Deng W; Ueda K; Wu G; Jayachandran G; Kondo S; Atkinson EN; Minna JD; Roth JA; Ji L
    Cancer Res; 2007 Jul; 67(13):6293-303. PubMed ID: 17616688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer.
    Prudkin L; Behrens C; Liu DD; Zhou X; Ozburn NC; Bekele BN; Minna JD; Moran C; Roth JA; Ji L; Wistuba II
    Clin Cancer Res; 2008 Jan; 14(1):41-7. PubMed ID: 18172250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3.
    Oh JJ; West AR; Fishbein MC; Slamon DJ
    Cancer Res; 2002 Jun; 62(11):3207-13. PubMed ID: 12036935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial Fus1/Tusc2 and cellular Ca2
    Uzhachenko R; Shimamoto A; Chirwa SS; Ivanov SV; Ivanova AV; Shanker A
    Cancer Gene Ther; 2022 Oct; 29(10):1307-1320. PubMed ID: 35181743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttranslational N-myristoylation is required for the anti-apoptotic activity of human tGelsolin, the C-terminal caspase cleavage product of human gelsolin.
    Sakurai N; Utsumi T
    J Biol Chem; 2006 May; 281(20):14288-95. PubMed ID: 16556605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.